Zoetis Inc. (NYSE:ZTS) Shares Bought by Investors Asset Management of Georgia Inc. GA ADV

Investors Asset Management of Georgia Inc. GA ADV increased its holdings in Zoetis Inc. (NYSE:ZTS) by 5.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,120 shares of the company’s stock after buying an additional 101 shares during the period. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Zoetis were worth $345,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of ZTS. AMF Tjanstepension AB raised its position in shares of Zoetis by 23.4% during the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after purchasing an additional 20,001 shares during the period. Howard Capital Management Group LLC grew its stake in Zoetis by 0.8% during the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after buying an additional 883 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in Zoetis by 8.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 55,696 shares of the company’s stock worth $10,882,000 after buying an additional 4,107 shares during the period. Raleigh Capital Management Inc. increased its position in Zoetis by 128.5% in the third quarter. Raleigh Capital Management Inc. now owns 361 shares of the company’s stock worth $71,000 after buying an additional 203 shares during the period. Finally, Commerzbank Aktiengesellschaft FI lifted its stake in Zoetis by 39.6% in the third quarter. Commerzbank Aktiengesellschaft FI now owns 2,590 shares of the company’s stock valued at $507,000 after buying an additional 735 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $157.38 on Friday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company’s 50-day moving average price is $166.86 and its two-hundred day moving average price is $178.14. The stock has a market cap of $70.47 billion, a PE ratio of 28.77, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ZTS. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Barclays raised their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Piper Sandler lowered their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Finally, Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Zoetis has an average rating of “Buy” and a consensus price target of $214.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.